TETANUS TOXOID BOOSTER Rx
Generic Name and Formulations:
Tetanus toxoid booster vaccine; for IM or SC inj; contains thimerosal.
Sanofi Pasteur, Inc.
Indications for TETANUS TOXOID BOOSTER:
Tetanus immunization booster.
Adults and Children:
<7yrs: not recommended. Give IM or SC in lateral mid-thigh or deltoid. ≥7yrs: After completion of primary immunization: 0.5mL every 10 years. Tetanus prophylaxis: see literature.
Not for primary immunization. History of systemic allergic or neurologic reactions to a previous dose of DT.
Latex allergy. Previous arthus-type hypersensitivity reaction: do not give more frequently than every 10 years. Defer in moderate or severe active respiratory or other febrile infection (may vaccinate if mild or minor illness) or during polio outbreak. Bleeding disorders (use SC route). Immunosuppressed. History of Guillain-Barre syndrome within 6 weeks of last tetanus vaccine. Have epinephrine (1:1000) available. Elderly. Pregnancy (Cat.C). Nursing mothers.
May get suboptimal response with immunosuppressants (eg, chemotherapy, high dose corticosteroids ≥2 weeks, radiation); consider deferring.
Local reactions (eg, erythema, tenderness), malaise, fever, hypotension, pain, nausea, arthralgia; rare: neurological disorders.
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness